What is Cerebrolysin?

Cerebrolysin is a research peptide in the Cognitive & Nootropic class. Porcine-derived neuropeptide mixture; neurotrophic and neuroprotective. It is studied at per-dose ranges of 5–30 mL IM/IV (Per cycle weekly), administered daily for 10–20 days over cycles of 2× per year. Supplied in Thailand by Thailand Peptides — Bangkok-based, research use only.

Peptide preparation with neurotrophic-factor-like activity. Registered in Europe/Asia for stroke and dementia.

Published and preclinical data are summarised below; dose ranges shown reflect protocols in the research literature and should be interpreted accordingly.

How does Cerebrolysin work?

Primary mechanism: Porcine-derived neuropeptide mixture; neurotrophic and neuroprotective. Research on Cerebrolysin implicates downstream effects on related signalling cascades, with magnitude and clinical relevance dependent on dose, timing, and individual pharmacogenomic factors.

Receptor binding affinity and post-receptor signalling for Cerebrolysin remain areas of active investigation; several proposed effects within the Cognitive & Nootropic class are currently supported only by in-vitro or rodent data, and should be interpreted accordingly.

Cerebrolysin dosage & protocol

Reference protocol for Cerebrolysin (research context only, drawn from published literature):

  • Per dose: 5–30 mL IM/IV
  • Weekly total: Per cycle
  • Frequency: Daily for 10–20 days
  • Cycle: 2× per year

Stacking Cerebrolysin

Commonly referenced pairing with Cerebrolysin: Semax. Stacking rationale should be grounded in complementary mechanisms, not additive speculation; interactions at shared receptors or enzymatic pathways should be accounted for. Both compounds in a Cerebrolysin stack are supplied by Thailand Peptides on the same order via the Bangkok research desk.

Contraindications

Status epilepticus. Additional caution is warranted in individuals with hepatic or renal impairment, endocrine disorders, or concurrent pharmacotherapy affecting the pathways described above.

Cerebrolysin — common questions

What is Cerebrolysin and what is it used for in research?
Cerebrolysin is classified within the Cognitive & Nootropic group. Peptide preparation with neurotrophic-factor-like activity. Registered in Europe/Asia for stroke and dementia. Research applications focus on the pathways outlined below. All references on this page describe published research only — Cerebrolysin is supplied for in-vitro and laboratory use, not for human consumption.
How does Cerebrolysin work?
Primary mechanism: Porcine-derived neuropeptide mixture; neurotrophic and neuroprotective. Downstream effects depend on dose, timing, and the biological system under investigation. Receptor binding and post-receptor signalling for Cerebrolysin remain areas of active study, and several proposed effects are supported only by preclinical data.
What is the typical Cerebrolysin research dose?
Published research protocols for Cerebrolysin describe per-dose ranges of 5–30 mL IM/IV, with a weekly total near Per cycle, administered daily for 10–20 days. Typical cycle: 2× per year. These ranges reflect the literature and are not dosing recommendations for any individual.
Where can I buy Cerebrolysin in Thailand?
Cerebrolysin is supplied by Thailand Peptides, a Bangkok-based research-peptide supplier. Orders are placed directly via WhatsApp to the Bangkok research desk — no cart, no account, no forms. Pricing and shipping are provided on request. Open a line with the research desk →
How fast can Cerebrolysin be delivered in Thailand?
Same-week delivery across Thailand is standard for orders confirmed within business hours (GMT+7, Monday–Saturday). Bangkok metro deliveries typically arrive within 1–3 business days; other provinces within 3–5. Regional Southeast Asia shipping is available on request.

Citations

  1. Muresanu DF, et al. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016. PMID: 26564102
  2. Heiss WD, et al. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial (CASTA). Stroke. 2012. PMID: 22282884

References curated from PubMed. Additional literature summarised in the Thailand Peptides research library.